Traditional Chinese medicine composition for treating heart failure and preparation method thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating the heart failure and a preparation method thereof, and relates to the technical field of traditional Chinese medicine. Raw materials of the traditional Chinese medicine composition comprise the following components in parts by weight: 5-9 parts of astragalus membranaceus, 3-7 parts of radix salviae miltiorrhizae, 3-7 parts of radix ophiopogonis, 1-3 parts of poria cocos, 1-3 parts of herba lycopi, 1-2 parts of angelica sinensis, 2-4 parts of radix rehmanniae, 1-2 parts of fructus aurantii, 1-2 parts of platycodon grandiflorum, 1-3 parts of prepared liquorice root, 1-2 parts of cooked rhubarb and 1-2 parts of leech. The traditional Chinese medicine composition is used for treating the chronic heart failure caused by cardiovascular diseases such as the coronary heart disease, the hypertension and the like, and the heart failure belongs to deficiency of both qi and yin and obstruction of collaterals by blood stasis, and shows the symptoms of palpitation and shortness of breath, dyspnea, chest distress and chest pain, spontaneous perspiration and night sweat, lack of breath and laziness to speak, limb edema and the like.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating heart failure and a preparation method thereof. Background technique [0002] Chronic heart failure (CHvv), also known as chronic heart failure, is a severe stage of heart disease caused by various reasons. Chronic heart failure (CHF) is the terminal stage of various cardiovascular and non-cardiovascular diseases, and its process is a chronic pathological and physiological development process from the compensatory stage to the decompensated stage. According to the hospitalization of the patients, 65% to 70% of them are accompanied by chronic heart failure (30% to 50% of the patients are mainly diagnosed with heart failure), and 80% of the patients are over 65 years old. Statistical surveys show that the prevalence of heart failure is gradually increasing, and the age of onset of patients is also gradua...

AI Technical Summary

Problems solved by technology

In recent years, modern medicine has conducted extensive and in-depth research on the pathophysiology, immune regulation, cardiac endocrine, and preventive treatment of chronic heart failure, especially angiotensin-converting enzyme inhibitors, calcium channel blockers, and beta receptor blockers. The use of drugs such as stagnation agents prolongs and saves the lives of some patients with heart failure. However, there are still many difficult problems in clinical treatment, such as the therapeutic dose of digitalis is close to the poisoning dose (about 60% of the poisoning dose) ), easy to overdose digitalis, so there are many contraindications and application limits; long-term use of diuretics can cause changes in blood lipids, blood sugar and uric acid metabolism, which is unfavorable for patients with hyperlipidemia, diabetes and gout; angiotensin Converting enzyme inhibitor (ACEI) acts on the renin-angiotensin-aldosterone system (RAAS) to block the conversion of angiotensin I to angiotensin II, acts on kininase II, inhibits the degradation of bradykinin, and reduces Aldosterone production, which delays ventricular remodeling and prevents further heart enlargement

Therefore, ACEI is recommended as the first-line drug for CHF patients with reduced left ventricular systolic function and left ventricular ejection fraction (LVEF) <45%. Cough is a common adverse reaction, which often leads to drug withdrawal; β-receptor blockers are recommended for the treatment of CHF patients of various degrees. Such drugs need to be taken for a long time to be effective, and there are three contraindications: bronchial asthma, Bradycardia, arrhythmia, and severe heart failure; therefore, modern medical treatment of heart failure is still based on the rational selection of drugs based on the specific conditions of the patient, timely adjustment, and individualized treatment in order to achieve the best curative effect and minimize side effects

Traditional Chinese medicine has accumulated a certain amount of experience in the treatment of heart failure, and has certain advantages compared with modern medicine. However, the existing clinical reports of traditional Chinese medicine are mainly based on the observation of clinical efficacy of traditional Chinese medicine decoction. There is a shortage of Chinese patent medicines for heart failure, and the only few Chinese patent medicines are relatively backward due to their preparation technology and content control

Therefore, the improvement of the preparation process of traditional Chinese medicine is still a big problem that plagues the clinical application of traditional Chinese medicine.

Images